

REFERENCES

- Andersen PS, Stryhn A, Hansen BE, Fugger L, Engberg J, Buus S. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. *Proc Natl Acad Sci* 1996; 93: 1820-24.
- Armstrong J, Perham RN, Walker JE. Domain structure of the bacteriophage fd adsorption protein. *FEBS Lett* 1981; 135: 167-72.
- Atwell JL, Breheny KA, Lawrence LJ, McCoy AJ, Kortt AA, Hudson PJ. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH, and VL domains dictates precisely the transition between diabodies, and triabodies. *Protein Eng* 1999; 12: 597-604.
- Azzazy HME, Highsmith WE Jr. Phage display technology: clinical applications and recent innovations. *Clin Biochem* 2002; 35: 425-45.
- Balint RF, Larrick JW. Antibody engineering by parsimonious mutagenesis. *Gene* 1993; 137: 109-18.
- Better M, Chang CP, Robinson RR, Horwitz AH. *Escherichia coli* secretion of an active chimeric antibody fragment. *Science* 1988; 240: 1041-3.
- Bourne Y, Talley TT, Hansen SB, Taylor P, Marchot P. Crystal structure of α Cbtx-AChBP complex reveals essential interactions between snake α -neurotoxins and nicotinic receptors. *EMBO J* 2005; 24: 1512-22.
- Brejč K, Dijk WJ, Klaassen RV, Schuurmans M, van Der Oost J, Smit AB, Sixma TK. Crystal structure of an Ach-binding protein reveals the ligand-binding domain of nicotinic receptors. *Nature* 2001; 411: 269-76.
- Byeon WH, Weisbluum B. Affinity adsorbent based on combinatorial phage display peptides that bind alpha-cobratoxin. *J Chromatogr B Analyt Technol Biomed Life Sci* 2004; 805: 361-3.
- Cai X, Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. *Proc Natl Acad Sci* 1995; 92: 6537-41.

- Cardoso DF, Mota I. Effect of *Crotalus* venom on the humoral and cellular immune response. *Toxicon* 1997; 35: 607-12.
- Chaicumpa W, Thin-Inta W, Khusmith S, Tapchaisri P, Echeverria P, Kalambaheti T. Detection with monoclonal antibody of *Salmonella typhi* antigen 9 in specimens from patients. *J Clin Microbiol* 1988; 26: 1824-30.
- Chester KA, Begent RH, Robson L, Keep P, Pedley RB, Boden JA. Phage libraries for generation of clinically useful antibodies. *Lancet* 1994; 343: 455-6.
- Chippaux JP, Goyffon M. Venoms, antivenoms, and immunotherapy. *Toxicon* 1998; 36: 823-46.
- Chippaux JP. Snake-bites: appraisal of the global situation. *Bull WHO* 1998; 76: 515-24.
- Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. *J Mol Biol* 1987; 196: 901-17.
- Chotwiwatthanakun C, Pratanaphon R, Akesowan S, Sriprapat S, and Ratanabanangkoon K. Production of potent polyvalent antivenom against three elapid venoms using a low dose, low volume, multi-site immunization protocol. *Toxicon* 2001; 39: 1487-94.
- Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. *Nature* 1991; 352: 624-8.
- Cohn EJ, Strong LE, Hughes WL, Mulford DJ, Ashworth, JN, Melin M, *et al.* Preparation and properties of serum and plasma proteins IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. *J Am Chem Soc* 1946; 68: 459-75.
- Cook GP, Tomlinson IM. The human immunoglobulin V_H repertoire. *Immunol Today* 1995; 16: 237-42.
- Crissman JW, Smith GP. Gene-III protein of filamentous phages: evidence for a carboxy-terminal domain with a role in morphogenesis. *Virology* 1984; 132: 445-55.
- Dall'Acqua W, Carter P. Antibody engineering. *Curr Opin Struct Biol* 1998; 8: 443-50.

- de Kruif J, Terstappen L, Boel E, Logtenberg T. Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. *Proc Natl Acad Sci USA* 1995; 92: 3938-42.
- Delahunty C, Yates JR III. Protein identification using 2D-LC-MS/MS. *Methods* 2005; 35: 248-55.
- Deng LW, Malik P, Perham RN. Interaction of the globular domains of pIII protein of filamentous bacteriophage fd with the F-pilus of *Escherichia coli*. *Virology* 1999; 253: 271-7.
- Dennis EA. Phospholipases. In: Boyer P. Ed. *The Enzymes* vol. 16. 3rd ed. New York; Academic Press, 1983: 307-53.
- Deraniyagala PEP. The taxonomy of the cobra of south-eastern asia. *Spolia Zeylanica* 1960; 29: 41-63.
- Dillman RO, Shawler DL, Dillman JB. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. *J Clin Oncol* 1984; 2: 881-91.
- Doley R, King GF, Mukherjee AK. Differential hydrolysis of erythrocyte and mitochondrial membrane phospholipids by two phospholipase A₂ isoenzymes (NK-PLA₂-I and NK-PLA₂-II), from Indian monocled cobra *Naja kaouthia* venom. *Arch Biochem Biophys* 2004; 425: 1-13.
- Doley R, Mukherjee AK. Purification and characterization of an anticoagulant phospholipase A₂ from Indian monocled cobra (*Naja kaouthia*) venom. *Toxicon* 2003; 41: 81-91.
- dos Santos MC, D'Impe'rio Lima MRD, Furtado GC, Colletto GMDD, Kipnis L, Dias da Silva W. Purification of F(ab')₂ anti-snake venom by caprylic acid: a fast method for obtaining IgG fragments with high neutralization activity, purity and yield. *Toxicon* 1989; 27: 297-303.
- Dufton MJ, Hider RC. The structure and pharmacology of elapid cytotoxins. In: Harvey AL. Ed. *Snake Toxins*. New York; Pergamon Press, 1991: 259-302.
- Eggertsen G, Lind P, Sjoquist J. Molecular characterization of the complement activating protein in the venom of the Indian cobra (*Naja naja siamensis*). *Mol Immunol* 1981; 18: 125-33.

- Endemann H, Model P. Location of filamentous phage minor coat proteins in phage and in infected bacteria. *J Mol Biol* 1995; 25: 496-506.
- Fritzinger DC, Bredehorst R, Vogel CW. Molecular cloning and derived primary structure of cobra venom factor. *Proc Natl Sci USA* 1994; 26: 12775-9
- Fruchart-Gaillard C, Gilquin B, Antil-Delbeke S. Experimentally based model of a complex between a snake toxin and the $\alpha 7$ nicotinic receptor. *PNAS* 2002; 99: 3216-21.
- Fujimura Y, Titani K. Structure and function of von Willebrand factor. In: Bloom AL, Forbes CD, Thomas D, and Tuddenham EGD, Eds. *Haemostasis and Thrombosis*. 3rd ed. Edinburgh, Scotland, Churchill Livingstone, 1993: 379-95.
- Garrard LJ, Henner DJ. Selection of an anti-IGF-1 Fab from a Fab phage library created by mutagenesis of multiple CDR loops. *Gene* 1993; 128: 103-9.
- Goldsby RA, Kindt TJ, Osborne BA. Organization and expression of immunoglobulin genes. In: *Kuby Immunology*. 4th ed. WH Freeman and Company. pp 115-47.
- Grandbois M, Clausen-Schaumann H, Gaub H. Atomic force microscope imaging of phospholipids bilayer degradation by phospholipase A₂. *Biophys J* 1998; 74: 2398-404.
- Gray CW, Brown RS, Marvn DA. Adsorption complex of filamentous fd virus. *J Mol Biol* 1981; 5: 621-7.
- Greenwood J, Willis AE, Perham RN. Regulation of bacteriophage length by modification of electrostatic interactions between coat protein and DNA. *J Mol Biol* 1991; 217: 223-7.
- Gregory-Dwyer VM, Egen NB, Bosisio AB, Righetti PG, Russell FE. An isoelectric focusing study of seasonal variation in rattlesnake venom proteins. *Toxicon* 1986; 24: 995-1000.
- Hamako J, Matsui T, Nishida S, Nomura S, Fujimura Y, Ito M, Ozeki Y, Titani K. Purification and characterisation of kaouthiagin, a von Willebrand factor-binding and cleaving metalloproteinase from *Naja kaouthia* cobra venom. *Thromb Haemost* 1998; 80: 499-505.
- Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. *J Mol Biol* 1992; 226: 889-96.

- Hay FC, Westwood OMR. Monoclonal antibodies: production, purification and enzymatic fragmentation. In: Practical Immunology. 4th ed. Oxford, Blackwell Publishing Company, 2002.
- Hayden MS, Gilliland LK, Ledbetter JA. Antibody engineering. *Curr Opin Immunol* 1997; 9: 201.
- Hesketh AR, Chandra G, Shaw AD, Rowland LL, Kell DB, Bibb MJ, Chayer KF. Primary and secondary metabolism, and post-translational protein modifications, as portrayed by proteomic analysis of *Streptomyces coelicolor*. *Mol Micro* 2002; 46: 917-32.
- <http://epid.moph.go.th>. Annual epidemiological surveillance report, Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health. ISSN 0857-6521. Accessed on Jan 7, 2005.
- <http://vbase.mrc-cpe.cam.ac.uk/vbase1/primers2.php>. V BASE: the database of human antibody genes. Accessed on Jan 20, 2005.
- <http://www.saovabha.org/snake/thai.php>. Saovabha Memorial institute, Thai Red Cross Society, Thailand. Accessed on Feb 25, 2008
- Huang MZ, Wang QC, Liu GF. Effects of an acidic phospholipase A2 purified from *Ophiophagus hannah* (king cobra) venom on rat heart. *Toxicon* 1993; 31: 627-35.
- Ito M, Hamako J, Sakurai Y, Matsumoto M, Fujimura Y, Suzuki M, *et al*. Complete amino acid sequence of kaouthiagin, a novel cobra venom metalloproteinase with two disintegrin-like sequences. *Biochemistry* 2001; 40: 4503-11.
- Jang JY, Kumar TKS, Jayaraman G, Yang PW, Yu C. Comparison of the hemolytic activity and solution structures of two snake venom cardiotoxin analogues which only differ in their N-terminal amino acid. *Biochemistry* 1997; 36: 14635-41.
- Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. *Nature* 1986; 321: 522-5.
- Kang AS, Barbas CF, Janda KD, Benkovic SJ, Lerner RA. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. *Proc Natl Acad Sci USA* 1991; 88: 4363-66.

- Karlsson E, Arnberg H, Eaker D. Isolation of the principal neurotoxins of two *Naja naja* subspecies. *Eur J Biochem* 1971; 21: 1-16.
- Karlsson E. Chemistry of protein toxins in snake venoms. In: Lee CY. Ed. *Snake Venoms. Handbook of Experimental Pharmacology*. New York, Springer-Verlag, 1979: 159-212.
- Kawamura Y, Sawai Y. Study on the immunogenicity of purified toxoid of Siamese cobra (*Naja naja kaouthia*) venom. *Snake* 1989; 21:81-4.
- Kini RM. Excitement ahead: structure, function and mechanism of snake venom phospholipase A₂ enzymes. *Toxicon* 2003; 42: 827-40.
- Kinter M, Sherman NE, Protein sequencing and identification using tandem mass spectrometry. 2000; ISBN 0-471-32249-0. Copyright © Wiley-Interscience, Inc.
- Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 1975; 256: 495-7.
- Krebber A, Burmester J, Plukthun A. Inclusion of an upstream transcriptional terminator in phage display vectors abolishes background expression of toxic fusions with coat protein g3p. *Gene* 1996; 178: 71-4.
- Kremser A, Rasched I. The adsorption protein of the filamentous phage fd: Assignment of its disulfide bridges and identification of the domain incorporated in the coat. *Biochemistry* 1994; 33: 13954-8.
- Kumar TKS, Jayaraman G, Lee CS *et al.* Snake venom cardiotoxins-structure, dynamics, function and folding. *J Biomol Struct Dyn* 1997; 5(3): 431-63.
- Kumar TKS, Lee CS, Yu C. *Natural Toxins II*. In: Tu AT, Singh BR Eds. New York, Plenum Press, 1996: 115-29.
- Laemmli UK. Cleavage of structural protein during the assembly of the head of bacteriophage T4. *Nature* 1970; 227: 680-5.
- Lang IM, Barbas CF 3rd, Schleef RR. Recombinant rabbit Fab with binding activity to type-1 plasminogen activator inhibitor derived from a phage-display library against human alpha-granules. *Gene* 1996; 172: 295-8.
- Lee CY. Chemistry and pharmacology of polypeptide toxins in snake venom. *Ann Rev Pharmacol* 1972; 12: 265-81.
- Lewis SM. The mechanism of V(D)J rejoining: lessons from molecular, immunological, and comparative analysis. *Adv Immunol* 1994; 56: 127-50.

- Li S, Wang J, Zhang X, Ren Y, Wang N, Zhao K, Chen X. Proteomic characterization of two snake venoms: *Naja naja atra* and *Agkistrodon halys*. *Biochem J* 2004; 384: 119-27.
- Limithongkul S, Pochanugool C, Benyajati C, Meemano K. Respiratory muscle fatigue in cobra bite treated patients. *J Med Assoc Thai* 1987; 70: 626-30.
- Losman MJ, Dejager RL, Monestier M, Sharkey RM, Goldenberg DM. Human immune response to anti-carcinoembryonic antigen murine monoclonal antibodies. *Cancer Res* 1990; 50 (Suppl): 1055s-8s.
- Low B. Venom toxin. In: *Handbook of Experimental Pharmacology*. Lee CY. Ed. Berlin, Springer, 1979; 52: 213-57.
- Makowski L. Terminating a macromolecular helix structural model for the minor proteins of bacteriophage M13. *J Mol Biol* 1992; 228: 885-92.
- Malmborg AC, Duenas M, Ohlin M, Soderlind E, Borrebaeck CA. Selection of binders from phage displayed antibody libraries using the BIAcore biosensor. *J Immunol Methods* 1996; 198: 51-7.
- Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, Winter G. By-passing immunization: building high affinity human antibodies by chain shuffling. *Biotechnology (NY)* 1992; 10: 779-83.
- Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. *J Mol Biol* 1991; 222: 581-97.
- Marvin DA, Hale RD, Nave C, Helmer CM. Molecular models and structural comparisons of native and mutant class I filamentous bacteriophages. *J Mol Biol* 1994; 235: 260-86.
- Marvin DA. Filamentous phage structure, infection and assembly. *Curr Opin Struct Biol* 1998; 8: 150-8.
- McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. *Nature* 1990; 348: 552-4.
- Mead DA, Kemper B. Chimeric single-stranded DNA phage-plasmid cloning vectors. *Biotechnology (NY)* 1988; 10: 85-102.
- Meeker TC, Lowder JN, Maloney DG *et al.* A clinical trial of anti-idiotypic therapy for B cell malignancy. *Blood* 1985; 65: 1349-63.

- Meng QX, Wang WY, Lu QM *et al.* A novel short neurotoxin, cobrotoxin c, from monocellate cobra (*Naja kaouthia*) venom: isolation and purification, primary and secondary determination, and tertiary structure modeling. *Comp Biochem Physio* 2002; 132: 113-21.
- Miura S, Sakurai Y, Takatsuka H, Yoshioka A, Matsumoto M, Yagi H *et al.* *Br J Haematol* 1999; 105: 1092-100.
- Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. *Proc Natl Acad Sci USA* 1984; 81: 6851-5.
- Mukherjee AK, Ghosal SK, Maity CR. Lysosomal membrane stabilization by alpha-tocopherol against the damaging action of *Vipera russelli* venom phospholipase A₂. *Cell Mol Life Sci* 1997; 53: 152-5.
- Mukherjee AK. Correlation between the phospholipids domains of the target cell membrane and the extent of *Naja kaouthia* PLA₂-induced membrane damage: evidence of distinct catalytic and cytotoxic sites in PLA₂ molecules. *Biochimica et Biophysica Acta* 2007; 1770: 187-95.
- Nelson BK. Snake envenomation: incidence, clinical presentation, and management. *Med Toxicol* 1989; 4:17-31.
- Nikolayenko IV, Galkin OY, Grabchenko NI, Spivak MY. Preparation of higher purified human IgG, IgM, and IgA for immunization and immunoanalysis. *Ukrainica Bioorganica Acta* 2005; 2: 3-11.
- Nirathanan S, Gopalakrishnakone P, Gwee MCE, Khoo HE, Kini RM. Non-conventional toxins from elapid venoms. *Toxicon* 2003; 41: 397-407.
- Nissim A, Hoogenboom HR, Tomlinson IM, *et al.* Antibody fragments from a single pot phage display library as immunochemical reagents. *EMBO* 1994; 13: 692-8.
- Oettinger MA, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. *Science* 1990; 248: 1517-23.
- Osipov AV, Mordvintsev DY, Starkov VG, Galebskaya LV, Bel'tyukov PP, Kozlov LV, Romanov SV. *Naja melanoleuca* cobra venom contains two forms of complement-depleting factor (CVF). *Toxicon* 2005; 46: 394-403.

- Osipov AV, Leashow MY, Tsetlin VI, Utkin YN. Cobra venom contains a pool of cysteine-rich secretory protein. *Biochem Biophys Res Commun* 2005; 328: 177-82.
- Padlan EA. Anatomy of the antibody molecule. *Mol Immunol* 1994; 31:169-217.
- Pasqualini R, Ruoslahti E. Organ targeting *in vivo* using phage display peptide libraries. *Nature* 1996; 380: 364-6.
- Pimm MV, Perkins AC, Armitage NC, Baldwin RW. The characteristics of blood-borne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabeled monoclonal antibody in cancer patients. *J Nucl Med* 1985 ; 26: 1011-23.
- Pithayanukul P, Ruenraroengsak P, Bavovada R, Pakmanee N, Suttisri R, Saen-oon S. Inhibition of *Naja kaouthia* venom activities by plant polyphenols. *J Ethnopharmacol* 2005; 97(3): 527-33.
- Popov S, Hubbard JG, Ward ES. A novel, and efficient route for the isolation of antibodies that recognize T cell receptor V alpha(s). *Mol Immunol* 1996; 33: 493-502.
- Raba R, Aaviksaar A, Raba M, Siigur J. Cobra venom acetylcholinesterase. Purification and molecular properties. *Eur J Biochem* 1979; 96: 151-8.
- Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. *Am J Hyg* 1938; 27: 493-7.
- Reid CE, Spencer HG. Ultrafiltration of salt solutions by ion-excluding and ion-selective membracens. *J Appl Pol Sci* 2003; 4: 354-61.
- Roberts BL, Markland W, Siranosian K, Saxena MJ, Guterman SK, Ladner RC. Protease inhibitor display M13 phage: selection of high-affinity neutrophil elastase inhibitors. *Gene* 1992; 121: 9-15.
- Roitt IM, Delves PJ. *An encyclopedia of immunology*. 2nd ed. London, Academic Press, 1998.
- Rokonjac J, Feng JN, Model P. Filamentous phage are released from the bacterial membrane by a two-step mechanism involving a short C-terminal fragment of pIII. *J Mol Biol* 1999; 289: 1253-65.
- Schatz DG, Oettinger MA, Schlissel MS. V(D)J recombination: molecular biology and regulation. *Annu Rev Immunol* 1992; 10: 359-83.

- Scott JK, Barbas III CF. Phage display vector. In: Barbas III CF, Burton DR, Scott JK, Silverman GJ. Eds. Phage display: A Laboratory Manual. New York, Cold Spring Harbor Laboratory Press, 2001.
- Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in *Escherichia coli*. Science 1988; 240: 1038-41.
- Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228: 1315-7.
- Specthrie L, Bullitt E, Horiuchi K, Model P, Russel M, Makowski L. Construction of a microphage variant of filamentous bacteriophage. J Mol Biol 1992; 228: 720-4.
- Stengle I, Bross P, Garces X, Giray J, Rasched I. Dissection of functional domains on phage fd adsorption protein-discrimination between attachment and penetration sites. J Mol Biol 1990; 212: 143-9.
- Sunthornandh P, Matangkasombut P, Ratanabanangkoon K. Preparation, characterization and immunogenicity of various polymers and conjugates of elapid post-synaptic neurotoxin. Mol Immunol 1992; 29: 501-10.
- Sunthornandh P, Ratanabanangkoon K. A comparative study of three vehicles on antibody responses against elapid snake neurotoxin immunogens. Toxicol 1994; 32: 561-71.
- Sutherland SK, Coulter AR, Harris RD. Rationalisation of first-aid measures for elapid snakebite. Lancet 1979; 1: 183-5.
- Theakston RD, Warrell DA. Crisis in snake antivenom supply for Africa. Lancet 2000; 356: 2104.
- Tomlinson IM, Cox JP, Gherardi E, Lesk AM, Chothia C. The structure repertoire of the human V kappa domain. EMBO J 1995; 15: 4628-38.
- Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302: 575-81.
- Tsetlin V. Snake venom alpha-neurotoxins and other 'three-finger' proteins. Eur J Biochem 1999; 264: 281-6.
- Vaughan TJ, Williams AJ, Pritchard K. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotech 1996; 14: 309-14.

- Viravan C, Veeranutvat V, Warrell MJ, Theakston RDG, Warrell DA. ELISA confirmation of acute and past envenoming by the monocellate Thai cobra (*Naja kaouthia*). *Am J Trop Med Hyg* 1986; 35: 173-81.
- von Zabern I, Pyklenk H, Vogt W. Chain structure of cobra venom factor from *Naja naja* and *Naja haje* venom. *Scand J Immunol* 1982; 4: 357-62.
- Walkinshaw MD, Saenger W, Maelicke A. Three-dimensional structure of the "long" neurotoxin from cobra venom. *Proc Natl Acad Sci USA* 1980; 77: 2400-4.
- Ward RL, Clark MA, Lees J, Hawkins NJ. Retrieval of human antibodies from phage-display libraries using enzymatic cleavage. *J Immunol Methods* 1996; 189: 73-82.
- Warrell DA. The clinical management of snake bites in the Southeast Asian region. *Southeast Asian J Trop Med Public Health* 1999; 30 (supplement): 1-84.
- Washburn MP, Wolters D, Yates III, JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. *Nat Biotechnol* 2001; 19: 242-47.
- Webster R. Filamentous phage biology. In: Barbas III CF, Burton DR, Scott JK, Silverman GJ. Eds. *Phage display: A Laboratory Manual*. New York, Cold Spring Harbor Laboratory Press, 2001.
- Wei JF, Lu QM, Jin Y, Li DS, Xiong YL, Wang WY. Alpha-neurotoxins of *Naja atra* and *Naja kaouthia* snakes in different regions. *Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)* 2003; 35: 683-8.
- Wernucke JF, Oberjat T, Howard BD. Beta-neurotoxin reduces neurotransmitter storage in brain synapses. *J Neurochem* 1974; 22: 781-8.
- Williams SC, Frippiat JP, Tomlinson IM, Ignatovich O, Lefranc MP, Winter G. Sequence and evolution of the human germ line V lambda repertoire. *J Mol Biol* 1996; 264: 220-32.
- Winter G and Milstein C. Man made antibodies. *Nature* 1990; 349: 293.
- Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. *Annu Rev Immunol* 1994; 12: 433-55.
- Wong JYC, Chu DZ, Yamauchi DM, William LE, Liu A, Wilczynski S, Wu AM. A phase I radioimmunotherapy trial evaluating ⁹⁰yttrium-labeled anti-

- carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. *Clin Cancer Res* 2000; 6: 3855-63.
- World Health Organization. Snake venoms and anti-venom. WHO Expert Committee on Biological Standardization. Technical report series no. 745. Geneva, 1987; 16.
- www.accessexcellence.org/AB/GG/monoclonal.html, Accessed on Feb 25, 2008
- Yamanaka HI, Inoue T, Ikeda-Tanaka O. Chicken monoclonal antibody isolated by a phage display system. *J Immunol* 1996; 157: 1156-62.
- Yang CC. Chemistry and evolution of toxins in snake venom. *Toxicon* 1974; 12: 1-43.
- Yang CC. Structure and function of cobra neurotoxin. *Adv Exp Med Biol* 1996; 391: 85-96.
- Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakibovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. *Cancer Res* 1999; 59: 1236-43.